Frequently Asked Questions

VIJOICE® (alpelisib) tablets

Find answers to common questions about VIJOICE and PROS

Expand all

VIJOICE® (alpelisib) tablets is a prescription medicine used to treat adults and children 2 years of age and older with severe phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA)-Related Overgrowth Spectrum (PROS).

It is not known if VIJOICE is safe and effective in children younger than 2 years of age.


Learn more about VIJOICE here.

VIJOICE® (alpelisib) tablets is a targeted therapy. VIJOICE targets the PI3Kα protein made by the PIK3CA gene. A mutation to this gene is the underlying cause of PIK3CA-Related Overgrowth Spectrum, or PROS. Targeted therapies can also affect healthy cells.

VIJOICE® (alpelisib) tablets is a once-daily tablet or tablets that should be taken by mouth, with food, and at the same time each day. For people who are unable to swallow tablets, VIJOICE can be crushed and made into a mixture with water.


Find step-by-step instructions here.

In a clinical study, people experienced a reduction in the size of overgrowths and an improvement in PIK3CA-Related Overgrowth Spectrum, or PROS, signs and features. They also saw improvements in their ability to do things.


Learn more about the safety and efficacy of VIJOICE® (alpelisib) tablets here.

Novartis offers financial assistance, help with accessing treatment, and ongoing, 1-to-1 support to eligible patients. 


Find details about the VIJOICE® (alpelisib) tablets VIP ProgramTM here.


For information about available financial resources, click here.

PROS stands for PIK3CA-Related Overgrowth Spectrum. PROS is the name for a group of conditions that are caused by a mutation in a gene called PIK3CA. The term mutation means the gene isn’t working correctly.


In 2013, researchers proposed grouping abnormal growth, vascular conditions, and lymphatic conditions caused by PIK3CA mutations under the term PROS. By uniting these many different conditions under one new term, researchers hoped to improve diagnosis, help manage symptoms, and establish future clinical trials.


The term PROS was proposed at a 2-day workshop that included several researchers who have been studying this group of conditions and 3 representatives of patient-family support and advocacy organizations for people with these conditions. The criteria for PROS may change as research develops.

PIK3CA mutations are changes to a specific part of your DNA called the PIK3CA gene. These changes are what cause PIK3CA-Related Overgrowth Spectrum, or PROS, conditions.


Discover the link between PIK3CA mutations and your PROS condition here.